Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 48 of 95, showing 5 Applications out of 471 total, starting on record 236, ending on 240

# Protocol No Study Title Investigator(s) & Site(s)

236.

ECCT/20/06/01   IAVI C100
    Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults   
Principal Investigator(s)
1. Prof Walter Jaoko Godfrey Jaoko
Site(s) in Kenya
1. KAVI-Insitute of Clinical Research, KNH site (Nairobi City county)
 
View

237.

ECCT/20/05/03   A5381
    Observational Cohort to Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of Tenofovir-Lamivudine-Dolutegravir (TLD) for First- or Second-Line ART or with Rifampicin-Containing TB Treatment   
Principal Investigator(s)
1. Victor Mudhune
Site(s) in Kenya
Kisumu Clinical Research Center
 
View

238.

ECCT/20/05/02   COPCOV
    Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV)   
Principal Investigator(s)
1. Anthony Oliwa Etyang
Site(s) in Kenya
1. KEMRI - Centre for Geographic Medicine Research Coast (CGMRC) (Kilifi county)
2. KEMRI-Centre for Global Health Research (CGHR) (Kisumu county)
 
View

239.

ECCT/20/05/01   ChAdOx1 nCoV-19 trial
    A phase Ib/II single-blinded, randomised, controlled study to determine safety, immunogenicity and efficacy of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults in Kenya   
Principal Investigator(s)
1. George Warimwe
Site(s) in Kenya
KEMRI-CGMRC
 
View

240.

ECCT/20/04/03   518 & 525-SHAN6™
    Study Title: Safety and Immunogenicity Study of Full Schedule (3-Dose SHAN6™) or SHAN6™- SHAN 5®- SHAN6™ Versus the Licensed Vaccine SHAN 5® With bOPV and IPV When Administered Per National Immunization Schedule in Healthy Kenyan Infants.    Phase III, multi-center, randomized, active-controlled, open-label, three-arm, study in 690 infants who will receive a 3-dose primary series at 6, 10 and 14 weeks of age, of either 3-dose SHAN6™ or SHAN6™ – SHAN 5® + bOPV – SHAN6™ or SHAN 5® + bOPV – SHAN 5® + bOPV – SHAN 5® + bOPV + IPV, and a booster dose of either SHAN6™ or SHAN 5® + bOPV at 18 months of age   
Principal Investigator(s)
1. Bernhards Ogutu
2. Godfrey Allan Otieno
3. Videlis Nduba
4. Lucy Chepkurui Koech
5. samuel Gurrion Ouma
6. Janet Oyieko
Site(s) in Kenya
1. Ahero Clinical Trials Unit (Kisumu county)
2. KEMRI, Centre for Respiratory Diseases Research (CRDR) (Nairobi City county)
3. KEMRI Kondele Children’s Hospital (Kisumu county)
4. KEMRI / Walter Reed Project, Clinical Research Centre, Kericho (Kericho county)
5. KEMRI CGHR, CLINICAL RESEARCH CENTRE (Kisumu county)
6. KEMRI Centre forClinical Research(CCR)_Butere County Hospital (Kakamega county)
7. CRDR_Siaya Annex(Back-up site) (Siaya county)
 
View